AI in Healthcare October 17, 2024
Dave Pearson

The U.S. Food and Drug Administration has its hands full making sure medical AI products are safe, efficacious and trustworthy before they hit the market. The rise of ever-more-innovative iterations of the technology—not least generative AI—is only adding to the burden.

But fear not. The agency is prepared to handle its duties and responsibilities to the best of its considerable abilities. It just can’t do everything for everyone all at once. In fact, it could use a hand from other stakeholders.

This comes through between the lines of a special communication published in JAMA Oct. 15. Senior-authored by FDA commissioner Robert Califf, MD, the paper describes 10 duties the agency must juggle as part of the job. Here are...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Technology
Related Articles:
FDA updates definition of 'healthy'
FDA Clears Withings’ New Blood Pressure Monitor That Allows Providers to Communicate Directly with Patients
4 takeaways from the FDA’s first digital health advisory committee
FDA commissioner, a veteran cardiologist, highlights ongoing issues with US healthcare system
FDA commissioner urges health systems to strengthen AI quality oversight

Share This Article